Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by fredgoodwinsonon Apr 16, 2022 3:20pm
166 Views
Post# 34607742

RE:RE:RE:RE:Rutherrin

RE:RE:RE:RE:Rutherrin

Exactly that Patience - we`re left guessing for want of information.If it wasn`t for Roswell Park themselves we wouldn`t know that they`d been interested even now.

 

With our own clear run to the Clinic a business decision to deny Roswell right of use might have made sense as our purported ability to activate Rutherrin by external X-ray (one of a number of areas in which it is said to excel over TLD-1433) would entirely obviate the need for an internal source of radiation and thereby trump even a sophisticated device like Lumeda.

 

Was that the reality?

 

At SPIE 2018 it was suggested that the efficient uptake of Rutherrin into orthotopic lung tumour was the very reason for it to be a Trial candidate (see Conclusion extract below). Note that the anticipated limitation then was with activation and the requirement for very specifically localised light sources.

 

Conclusion: These results support the hypothesis that safe and efficient Rutherrin-mediated PDT is feasible due to improved photosensitizer localization to lung tumors tissue. Selective irradiation of the cancer lesions by strategic placement of the light source remains a requirement.

 

The little that we have been given to make sense of recently would appear to suggest the exact opposite i.e. that the compound can be generally activated by external low-dose x-ray but that refinements are now required (something other than Rutherrin?) to enable the drug to be adequately delivered in an intravenously injectable form?

 

Who can make sense of any of this but for whatever reason Roswell Park (who incidentally had a tried tested and explicitly articulated non-intravenous NSCLC delivery system for TLD-1433 that TLT might well consider for Rutherrin) never went ahead with their Trial.

 

For our compound not to be taken up in this indication following initial strong interest from a Globally pre-eminent Experimental Cancer Centre and the home of PDT itself was IMHO a sad day. Trust that there were very good reasons but as the prospect of our own Trial in NSCLC shows strong signs of dematerialising into the mists of an uncertain future I am - like you - left wondering what they might have been.

 

 

<< Previous
Bullboard Posts
Next >>